Denali climbs past Avlayah expectations with $3.6M in revenue

Summary

Denali Therapeutics' Hunter syndrome drug Avlayah generated $3.6M in revenue in its first quarter following an April launch, exceeding analyst expectations. Strong patient uptake indicates successful commercial performance for the newly launched therapy.